EBS - Emergent sets $50 price tag for OTC opioid overdose therapy Narcan
2023-04-20 12:45:47 ET
- Contract manufacturer Emergent BioSolutions ( NYSE: EBS ) announced Thursday that its recently approved over-the-counter (PTC) opioid overdose therapy Narcan would be priced at around $50 per carton.
- In March, when the FDA approved the nasal spray for OTC use as an emergency therapy for opioid overdose, the company expected to launch the product later this summer in U.S. stores and online retailers.
- Covered by commercial- and government-run health insurance plans, Emergent's ( EBS ) prescription-only opioid reversal therapy is already available in the market with a list price of $125 per carton.
- Government-run health insurance plans do not typically cover OTC products though there were exemptions during the pandemic for at-home COVID -19 tests.
- "A goal for the out-of-pocket retailer price is to be consistent with our public interest pricing for one carton of two 4 milligram doses," Emergent ( EBS ) said, adding that the current average price for public interest groups will be less than $50.
- Read: Seeking Alpha analyst Singular Research upgraded EBS to Buy in February, citing a potential approval for OTC Narcan.
For further details see:
Emergent sets $50 price tag for OTC opioid overdose therapy Narcan